Bevacizumab + INF-α-2a: safer and therefore less costly in mRCC

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1329, 2010-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab boosts INF-α-2a in metastatic renal cancer

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

PEG INF-α-2a/ribavirin cost effective for mild-chronic hep C

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 495, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Bevacizumab costly for ovarian cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 624, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Kidney transplant less costly with live donor

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 254, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Telithromycin less costly than clarithromycin for CAP

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 420, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite